Exchange Traded Concepts LLC Purchases 4,733 Shares of Eli Lilly and Company (NYSE:LLY)

Exchange Traded Concepts LLC boosted its position in Eli Lilly and Company (NYSE:LLY) by 13.9% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 38,810 shares of the company’s stock after acquiring an additional 4,733 shares during the period. Eli Lilly and Company accounts for 0.6% of Exchange Traded Concepts LLC’s investment portfolio, making the stock its 25th biggest position. Exchange Traded Concepts LLC’s holdings in Eli Lilly and Company were worth $29,961,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in LLY. Driehaus Capital Management LLC grew its holdings in Eli Lilly and Company by 94.2% in the 2nd quarter. Driehaus Capital Management LLC now owns 1,635 shares of the company’s stock worth $1,480,000 after acquiring an additional 793 shares during the last quarter. Aviso Wealth Management boosted its stake in shares of Eli Lilly and Company by 3.8% during the 2nd quarter. Aviso Wealth Management now owns 2,139 shares of the company’s stock valued at $1,936,000 after purchasing an additional 79 shares in the last quarter. Algert Global LLC boosted its stake in shares of Eli Lilly and Company by 27.9% during the 2nd quarter. Algert Global LLC now owns 504 shares of the company’s stock valued at $456,000 after purchasing an additional 110 shares in the last quarter. Creative Planning boosted its stake in shares of Eli Lilly and Company by 4.1% during the 2nd quarter. Creative Planning now owns 228,675 shares of the company’s stock valued at $207,038,000 after purchasing an additional 9,007 shares in the last quarter. Finally, Doheny Asset Management CA boosted its stake in shares of Eli Lilly and Company by 0.6% during the 2nd quarter. Doheny Asset Management CA now owns 3,880 shares of the company’s stock valued at $3,513,000 after purchasing an additional 24 shares in the last quarter. Institutional investors own 82.53% of the company’s stock.

Insider Activity at Eli Lilly and Company

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 900 shares of the company’s stock in a transaction that occurred on Friday, November 8th. The shares were sold at an average price of $803.38, for a total transaction of $723,042.00. Following the completion of the sale, the chief accounting officer now directly owns 5,480 shares of the company’s stock, valued at approximately $4,402,522.40. This represents a 14.11 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.13% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on LLY shares. Bank of America reaffirmed a “buy” rating and set a $997.00 target price on shares of Eli Lilly and Company in a research note on Tuesday, December 10th. Deutsche Bank Aktiengesellschaft cut their target price on shares of Eli Lilly and Company from $1,025.00 to $1,015.00 and set a “buy” rating on the stock in a research note on Monday, November 4th. Redburn Atlantic raised shares of Eli Lilly and Company to a “hold” rating in a research note on Monday, November 4th. Barclays lowered their price target on shares of Eli Lilly and Company from $1,025.00 to $975.00 and set an “overweight” rating for the company in a research report on Thursday, October 31st. Finally, Citigroup lifted their price target on shares of Eli Lilly and Company from $1,060.00 to $1,250.00 and gave the company a “buy” rating in a research report on Friday, October 25th. Four analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $1,002.22.

Eli Lilly and Company Stock Up 2.4 %

LLY opened at $784.78 on Monday. The company has a quick ratio of 0.97, a current ratio of 1.27 and a debt-to-equity ratio of 2.03. The firm has a 50 day moving average price of $776.69 and a 200-day moving average price of $848.83. Eli Lilly and Company has a twelve month low of $624.68 and a twelve month high of $972.53. The stock has a market capitalization of $745.01 billion, a price-to-earnings ratio of 84.84, a PEG ratio of 1.59 and a beta of 0.41.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Wednesday, October 30th. The company reported $1.18 earnings per share for the quarter, missing the consensus estimate of $1.52 by ($0.34). Eli Lilly and Company had a net margin of 20.48% and a return on equity of 71.08%. The company had revenue of $11.44 billion for the quarter, compared to analysts’ expectations of $12.09 billion. During the same period in the previous year, the firm earned $0.10 earnings per share. The firm’s revenue for the quarter was up 20.4% on a year-over-year basis. Equities research analysts forecast that Eli Lilly and Company will post 12.98 earnings per share for the current year.

Eli Lilly and Company announced that its Board of Directors has approved a share buyback plan on Monday, December 9th that allows the company to buyback $15.00 billion in shares. This buyback authorization allows the company to purchase up to 2% of its shares through open market purchases. Shares buyback plans are typically an indication that the company’s management believes its shares are undervalued.

Eli Lilly and Company Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 10th. Stockholders of record on Friday, February 14th will be issued a dividend of $1.50 per share. This represents a $6.00 annualized dividend and a dividend yield of 0.76%. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.30. The ex-dividend date is Friday, February 14th. Eli Lilly and Company’s payout ratio is presently 56.22%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.